Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Company Details
- Employees
- 385
- Founded
- -
- Address
- 105 West First Street, Boston,ma 02127,united States
- Phone
- 141794589327
- in****@****rtx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- crisprtx.com
- Keywords
- Gene Editing, Hematology, Immuno-Oncology.
- HQ
- Boston, MA
Crispr Therapeutics Questions
Crispr Therapeutics's helpline number is 141794589327
Crispr Therapeutics's website is crisprtx.com
Crispr Therapeutics's LinkedIn profile is https://www.linkedin.com/company/crispr-therapeutics
Crispr Therapeutics has
385 employees.
View email and phone details for 385
employees at Crispr Therapeutics.
Crispr Therapeutics's industry is
Biotechnology Research
Crispr Therapeutics's top competitors are
Alnylam Pharmaceuticals,
Vertex Pharmaceuticals,
Bluebird Bio,
Editas Medicine,
Tessera Therapeutics,
Moderna,
Verve Therapeutics,
Beam Therapeutics,
Sarepta Therapeutics,
Intellia Therapeutics, Inc..
Crispr Therapeutics's support email address is info@crisprtx.com
Crispr Therapeutics's categories are Biotechnology Research
Crispr Therapeutics's founding year is 2013
